Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
arcticnovartis

  • Cosentyx is the only IL-17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 

  • HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 

  • Approval marks fourth pediatric indication for Cosentyx, reinforcing its robust safety and efficacy profile1 
/by
Bringing proteins together to take cancer apart

Bringing proteins together to take cancer apart
halesmi2

/by
Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut

Aktionäre von Novartis heissen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats gut
arcticnovartis

  • Die Aktionärinnen und Aktionäre genehmigten die 29. Dividendenerhöhung in Folge. Für 2025 wird die Dividende auf CHF 3.70 (+5,7%) je Aktie erhöht, was einer Rendite von 3,0% entspricht¹

  • Die Aktionärinnen und Aktionäre bestätigten Giovanni Caforio als Vorsitzenden des Verwaltungsrats sowie alle weiteren Mitglieder des Verwaltungsrats die zur Wiederwahl standen. Charles Swanton wurde zum neuen Mitglied des Verwaltungsrats gewählt.
/by
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
arcticnovartis

  • Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹

  • Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as well as all other members of the Board of Directors who stood for re-election; Charles Swanton newly elected as member of the Board of Directors
/by
Supercharging R&D: How AI helps us to bring medicines to patients faster

Supercharging R&D: How AI helps us to bring medicines to patients faster
tavasat1

/by
Turning personal experience into purpose-driven careers

Turning personal experience into purpose-driven careers
tavasat1

/by
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
arcticnovartis

  • Adds Avidity’s differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipeline
  • Potentially unlocks multi-billion-dollar opportunities with planned product launches before 2030
  • Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook

/by
Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)
arcticnovartis

  • Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe
  • Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety profile including no liver safety concerns through Week 521
/by
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients
arcticnovartis

  • Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in US
  • Site to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor types
  • Company broke ground on 4 new manufacturing and R&D facilities, initiated 3 facility expansions, and announced 2 additional sites in last 10 months, rapidly making progress on its commitment to expand its US operations
/by
New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer
arcticnovartis

  • In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC
  • Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPIs
/by